Form 4 for SPRB SPRUCE BIOSCIENCES, INC.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-10 · accession 0001903669-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-12 | 2025-12-10+ | SPRB | Szwarcberg Javier B. | CEO, Dir | F - Tax | $87.96 | -2,622 | 10.2K | -20% | -$230.6K |
| DM | 2025-12-12 | 2025-12-10+ | SPRB | Szwarcberg Javier B. | CEO, Dir | M - OptEx | $0.00 | +6,146 | 15.2K | +68% | $0 |
| DM | 2025-12-12 | 2025-12-10+ | SPRB | Szwarcberg Javier B. | CEO, Dir | M - OptEx | $0.00 | -6,146 | 14.8K | -29% | $0 |
| D | 2025-12-12 | 2025-12-11 | SPRB | Szwarcberg Javier B. | CEO, Dir | A - Grant | $0.00 | +19.8K | 19.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-11 | F | D | 2,194 | $88.41 | 12,998 | D | — | — | (F3) 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. |
| 2 | Common | Common Stock | 2025-12-10 | F | D | 428 | $85.67 | 10,242 | D | — | — | (F1) On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. |
| 3 | Common | Common Stock | 2025-12-10 | M | A | 1,196 | $0.00 | 10,670 | D | — | — | (F1) On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. (F2) Each RSU represents a contingent right to receive one share of SPRB common stock. |
| 4 | Common | Common Stock | 2025-12-11 | M | A | 4,950 | $0.00 | 15,192 | D | — | — | (F3) 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. (F2) Each RSU represents a contingent right to receive one share of SPRB common stock. |
| 5 | Derivative | Restricted Stock Units | 2025-12-10 | M | D | 1,196 | $0.00 | 3,588 | D | $0.00 · — to — | 1,196 Common Stock | (F2) Each RSU represents a contingent right to receive one share of SPRB common stock. (F1) On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. |
| 6 | Derivative | Restricted Stock Units | 2025-12-11 | A | A | 19,800 | $0.00 | 19,800 | D | $0.00 · — to — | 19,800 Common Stock | (F2) Each RSU represents a contingent right to receive one share of SPRB common stock. (F3) 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. |
| 7 | Derivative | Restricted Stock Units | 2025-12-11 | M | D | 4,950 | $0.00 | 14,850 | D | $0.00 · — to — | 4,950 Common Stock | (F2) Each RSU represents a contingent right to receive one share of SPRB common stock. (F3) 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. |